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ABSTRACT
Objective: In this study, three-dimensional (3D) structures of lung cancer cell line proteins (cellular tumor antigen [p53], caspase 3, and mucosal 
addressin cell adhesion molecule 1) were generated, and their binding affinities with apigenin through local docking were studied.
Methods: The lung cancer cell line proteins were built using Swiss model and visualized by the PyMol software. The physicochemical characterization 
of the protein models was evaluated by Expasy’s ProtParam Proteomics server. Then, they were validated by PROCHECK, ProQ, ERRAT, and Verify 3D 
programs. Finally, the protein models were docked with apigenin using BSP-Slim server.
Results: All the protein models were acceptable and of good quality. The apigenin showed the binding energy with cellular tumor antigen (p53), 
caspase 3, and mucosal addressin cell adhesion molecule 1 at −4.611, −5.750, and −5.307 kcal/mol, respectively.
Conclusion: The caspase 3 had the strongest bond with apigenin. These potential drug candidates can further be validated in laboratory experiments 
for its proper function.
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INTRODUCTION
Lung cancer is the leading cause of death in Malaysia. In 2007, it is the 
third most common cancer after breast and colorectal cancer. It is the 
most common cancer diagnosed in men while fifth common cancer in 
women [1]. In 2006, 2948 lung cancer cases were reported (1445 in 
men and 603 in women). Moreover, 1.8 million lung cancer cases were 
estimated to have been diagnosed in 2012.
Even though the survival rate after a diagnosis of lung cancer made is 
49%; only <2% of cancer patients are still alive in 5 years if cancer has 
not spread to the other parts of the body. The incidence of lung cancer 
and consequent death from this disease is expected to increase over the 
next decade because of the high rates of smoking [1].
The mean age at which lung cancer is diagnosed in Malaysia is about 
60 years with a peak age of diagnosis in the 7th decade. The incidence of 
diagnosed lung cancer in Malaysian patients aged <40 years is generally 
low at about 6.2%. Based on the World Health Organization (WHO) 
performance status, younger patients were more likely than older 
patients to have adenocarcinoma with poorer. Late stage introduction 
and in this way inoperability is extremely normal in the more youthful 
age bunches as they more often than not stay asymptomatic or ignore 
symptoms longer [2]. In one study, all patients <40 years old with 
non-small cell lung cancer (NSCLC) presented with either Stage IIIb or 
metastatic disease, compared to 77% of older patients [3].
Lung cancer usually divided into 2 groups according to its type of 
cells. First is NSCLC which can be subdivided into three, namely 
adenocarcinoma (30–40%), squamous cell carcinoma (30%), and large 
cell carcinoma (10%). Second is small cell lung cancer (20%) which 
cancer cell grows at a very rapid rate and most of the time spread to 
other parts of the diagnosis. Other types of cancer can be found in the 
lungs are carcinoid and lymphoma (5%) [4]. Thus, the development 
of a therapeutic approach to lung cancer remains one of the most 
challenging areas in cancer research.
Plant compounds also have been identified as a class of promising 
anticancer agents. Apigenin, plant compound found in parsley, has over 
and again been found to have solid against malignancy properties. Truth 
be told, more than 600 PubMed-recorded diary articles identify with the 
compound’s part in the disease. In a look into distributed September 
2015 in Oncotarget, researchers interestingly could recognize how 
apigenin can successfully back off or stop an undesirable compound, 
which assumes a part in disease movement.
Apigenin has increased specific interest for many years as a valuable 
and well-being promoting agent due to its low inherent poisonous 
quality and in light of its striking impacts on normal versus tumor 
cells, contrasted and other fundamentally related flavonoids [5]. There 
is almost no confirmation to date to recommend that apigenin helps 
adverse metabolic responses in vivo when expended as a component 
of a normal eating regimen. Apigenin has been progressively perceived 
in the recent years as a tumor chemopreventive agent. A study shows 
where the consumption of free flavonoids in healthy human volunteers 
diets lead to decrease in markers of oxidative stress in blood, namely 
plasma antioxidant vitamins, erythrocyte superoxide dismutase 
activity, and lymphocyte DNA damage commonly associated with 
enhanced disease risk [6].
In mammalian systems either in vitro or in vivo, a few of the biological 
property of apigenin are identified such as antioxidant effects and its 
part scavenging free radicals. Besides that, it exhibits antimutagenic, 
anti-inflammatory, antiviral, and purgative impacts [7]. The activities 
of apigenin in inhibiting the cell cycle, reducing oxidative stress, 
enhancing the viability of detoxification enzymes, inducing apoptosis, 
and stimulating the immune system are quite limited.
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Johnson et al. study demonstrated that apigenin had the inhibitory 
effects on glycogen synthase kinase (GSK-3β) [8]. Inhibition of GSK-
3β causes decreased in the proliferation of pancreatic cancer cell 
and survival by abrogating nuclear factor κB activity [8]. Apigenin 
docked with GSK-3β. The binding energy of the apigenin - GSK-
3β complex was 76.1 kcal/mol. Furthermore, Way et al. study 
described that apigenin docked with PI3K [9]. Therefore, PI3K 
could not bind with HER2/HER3 heterodimer which causes breast 
cancer proliferation. Apigenin indirectly inhibited PI3K activity in 
AKT pathway, but the interaction mechanism between cancer cell 
line proteins and apigenin is yet to be elucidated. In this study, we 
report for the first time that the cellular tumor antigen p53, caspase 
3, and mucosal addressin cell adhesion molecule 1 interacts with 
apigenin.
The objective of this study is to generate three-dimensional (3D) 
structures of lung cancer cell line proteins (cellular tumor antigen 
p53, caspase 3, and mucosal addressin cell adhesion molecule 1) 




The complete amino acid sequence of the p53 (GI: 2491729), caspase 
3 (GI: 16516817), and mucosal addressin cell adhesion molecule 1 (GI: 
109633022) were obtained from National Center for Biotechnology 
Information. It consists of 393, 277, and 382 amino acids, respectively.
Homology modeling
To date, the 3D models of cellular tumor antigen p53, caspase 3, and 
mucosal addressin cell adhesion molecule 1 were not available. Hence, 
the models were generated using Swiss-Model (https://swissmodel.
expasy.org/) [10] and visualized by the PyMol software (http://www.
pymol.org/) [11].
Physiochemical characterization
Protein structural analysis was carried out through the Expasy’s 
ProtParam Proteomics server [12]. Non-polar and polar residues were 
determined by Color Protein Sequence (Colorseq) analysis [13]. The 
ESBRI program [14] was used to discover salt bridges in the protein 
models; the number of disulfide bonds was calculated using the Cys_Rec 
program [15].
Prediction of the secondary structures
The secondary structural features were predicted with Self-Optimized 
Prediction Method from Alignment (SOPMA) [16].
Evaluation of the protein models
The protein structures were validated with PROCHECK by 
Ramachandran plot analysis [17]. The model was further analyzed by 
ProQ [18], ERRAT [19], and verify 3D [20] programs.
Identification of active sites
To identify the binding sites of the cellular tumor antigen p53, caspase 
3, and mucosal addressin cell adhesion molecule 1, they were submitted 
to active site-prediction server [21].
Preparation of ligand model
The tertiary structure of the apigenin was not publicly available. The 
complete sequence of apigenin obtained from PubChem (https://
pubchem.ncbi.nlm.nih.gov/) [22]. Then, the structure was in structured 
data format . Thus, it was converted to protein data bank format using 
molecule file format conversion (through Chem Axon J Chem).
Protein–ligand docking
The 3D model of cellular tumor antigen p53 was performed for 
molecular docking with the 3D structure of apigenin using BSP-Slim 
server [23]. The top-ranked conformation with the lowest binding 
energy was selected [24]. The same docking simulation approach was 
performed with the other two protein molecules.
RESULTS AND DISCUSSION
Physiochemical characterization
The computed isoelectric point (pI) value for cellular tumor antigen 
p53, caspase 3, and mucosal addressin cell adhesion molecule 1 
(pI <7) indicated acidic characteristic. Moreover, p53, caspase 3, and 
mucosal addressin cell adhesion molecule 1 had a molecular weight of 
43683.16, 31641.92, and 40155.28 Daltons, respectively. Through the 
extent of light that is absorbed by a protein, the elimination coefficient 
of tyrosine, cysteine, and tryptophan residues was calculated at a 
specific wavelength, which is 31400–35410 M/cm. Moreover, ASP+GLU 
is the total number of negatively charged residues which are −R, and 
ARG+LYS is +R which is the total number of positively charged residues. 
Thus, there were was a sum of 50 negatively charged residues and 46 
positively charged residues for cellular tumor antigen p53 in the amino 
acid sequence, while caspase 3 had a total of 40 negatively charged 
residues and 36 positively charged residues in the amino acid sequence. 
Besides that, mucosal addressin cell adhesion molecule 1 had a sum of 
40 positively charged residues and 26 negatively charged residues in 
the amino acid sequence. Based on the Expasy’s ProtParam instability 
index, cellular tumor protein p53 and mucosal addressin cell adhesion 
molecule 1 proteins were classified as unstable because the instability 
index value was more than 40 which had an instability index value of 
71.93 and 63.75. However, caspase 3 can be classified as stable as it had 
stability index within the range.
The aliphatic list of all the protein models is shown in Table 1. The 
low grand average of hydropathicity (GRAVY) index (a negative 
esteem GRAVY) of all proteins is exhibited their hydrophilic nature 
(Table 1). Furthermore, cellular tumor antigen p53, caspase 3, and 
mucosal addressin cell adhesion molecule 1 had more polar residues 
(47.33, 49.10, and 41.36%) than nonpolar residues (24.94, 27.44, 
and 31.94%). This was determined using Color Protein Sequence 
analysis.
Salt bridges have an important role in the structure and stability 
of a protein. The interruption of a salt bridge reduces the protein 
stability [25]. It is additionally engaged with allosteric control, 
recognition of molecular, oligomerization, adaptability, area movements, 
and thermostability [26,27]. In this study, the cellular tumor antigen 
p53, caspase 3, and mucosal addressin cell adhesion molecule 1 had 6, 
6, and 6 salt bridges, respectively, which were obtained through ESBRI. 
They were formed by residues of arginine.
Table 1: Physiochemical characters of the cellular tumor antigen p53, caspase 3, and mucosal addressin cell adhesion molecule 1 as 
predicted by Expasy’s protParam program
Protein Length Molecular 
weight







Cellular tumor antigen p53 393 43683.16 6.37 50 46 35410 71.93 59.08 −0.758
Caspase 3 277 31641.92 6.09 40 36 31400 40.58 70.04 −0.472
Mucosal addressin cell 
adhesion molecule 1
382 40155.28 5.00 40 26 31970 63.75 84.27 −0.250
GRAVY: Grand average of hydropathicity
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The thermostability of a molecule is increased in the presence 
of arginine in the protein structure by giving more electrostatic 
interactions through their guanidine group [28]. Therefore, it ensured 
that all the proteins are in the same stability. From the analysis of 
Cys_Rec, it shows that the number of disulfide bonds in cellular tumor 
antigen p53, caspase 3, and mucosal addressin cell adhesion molecule 1 
had 10, 8, and 7, respectively (Table 2).
Prediction of the secondary structures
SOPMA view has demonstrated that the presence of random coils 
overwhelmed among secondary structure components took after by 
α-helix, broadened strand, and beta turns at different positions in proteins. 
The composition of α-helix in cellular tumor antigen p53, caspase 3, and 
mucosal addressin cell adhesion molecule 1 was shown in Table 3.
Results from this analysis indicated that cellular tumor antigen p53, 
caspase 3, and mucosal addressin cell adhesion molecule 1 consist of 
11, 12, and 15 α helices, respectively. The longest and shortest α helix of 
all proteins is described in Table 4.
Validation of the protein models
For the stereochemical quality and the geometry of protein models, they 
were validated by Ramachandran plot calculations through PROCHECK 
software (Fig. 1). From the analysis, it was confirmed that residues of 
all protein models are in a most favorable region which was more than 
80% (Table 5). Therefore, the quality of these proteins was evaluated 
to be great and dependable. PROCHECK analysis revealed that several 
residues such as ARG76, LEU194, ASP129, SER66, ASP64, ASP73, 
ASN145, and SER229 were situated out of energetically favored regions 
of Ramachandran plot for mucosal addressin cell adhesion molecule 
1. However, there were no residues found at the disallowed region for 
other two protein models.
Hence, the stereochemical evaluation of backbone phi/psi dihedral 
angles inferred that a low percentage of residues for cellular tumor 
antigen p53, caspase 3, and mucosal addressin cell adhesion molecule 1 
were falling within protein models. ProQ was used to verify “the quality” 
using the Levitt-Gerstein (LG) score and maximum subarray (MaxSub). 
The results show that the predicted LG score (>1.5: Good model) and 
predicted MaxSub score (>0.1 good model) for all protein structures 
were in the acceptable range to create a good model (Table 5).
ERRAT is an analysis for evaluating protein models determined by X-ray 
crystallography. ERRAT value depends on the statistics of nonbonded 
atomic interactions in the 3D protein structure. The normally accepted 
Table 2: Presence of disulfide (ss) bond predicted by Cys_Rec 
server
Protein Cys_Rec Score


















Mucosal addressin cell  








Table 3: Secondary structure of the cellular tumor antigen p53, caspase 3, and mucosal addressin cell adhesion molecule 1
Secondary structure α helix Extended strand Beta‑turn Random coil
Cellular tumor antigen p53 18.83 19.08 8.91 53.18
Caspase 3 35.02 17.33 9.75 37.92
Mucosal addressin cell adhesion molecule 1 28.27 14.40 6.28 51.05
Table 4: Composition of α‑helix in the cellular tumor antigen p53, caspase 3, and mucosal addressin cell adhesion molecule 1
Amino acid Longest α‑helix Residues Shortest α‑helix Residues
Cellular tumor antigen p53 α9 16 α8 1
Caspase 3 α9 36 α5, α8 1
Mucosal addressin cell adhesion molecule 1 α13 15 α2, α4 1
Table 5: Validation of the cellular tumor antigen p53, caspase 3, and mucosal addressin cell adhesion molecule 1

















p53 89.8 9.6 0.6 0.0 −0.33 −0.04 −0.20 4.527 0.478






82.2 10.7 5.3 1.8 −0.68 −0.39 0.53 4.212 0.348
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range is more than 50 % for a high-quality protein model. The result 
analysis of ERRAT score revealed that caspase 3 was the highest at 
98.492 (Fig. 2). Thus, it is confirmed that caspase 3 model has a good 
high resolution and quality model compared to other protein models. 
The scores for the cellular tumor antigen p53 and mucosal addressin 
cell adhesion molecule 1 were 93.514 and 86.928, respectively.
Cellular tumor antigen p53, caspase 3, and mucosal addressin cell 
adhesion molecule 1 had 85.71%, 71.49%, and 95.69% of the residues, 
respectively, which were revealed through verifying with the 3D server. 
It had an average 3D-1D score of more than 0.2. Hence, it indicates all 
the sequence were compatible with its protein model (Fig. 3). Finally, 
the resulting energy minimized cellular tumor antigen p53, caspase 
3, and mucosal addressin cell adhesion molecule 1 protein models 
fulfilled the criteria for the protein evaluation. Thus, docking analysis 
with ligand will proceed.
Identification of active sites
The protein volume of the active site and the residues forming a 
pocket of the active site for cellular tumor antigen p53, caspase 3, and 
molecular addressin cell adhesion molecule 1 were obtained using BSP 
Slim server (Table 6). The protein volume for cellular tumor antigen 
p53, caspase 3, and mucosal addressin cell adhesion molecule 1 is 1229, 
1164, and 938 A3, respectively.
Protein‑ligand docking
Two early human papillomavirus (HPV) genes, E6 and E7, are known 
to play crucial role in tumor formation. E6 binds with p53 and prevents 
its translocation and thereby inhibit the ability of p53 to activate or 
repress target genes. E7 binds to hypophosphorylated Rb and thereby 
induces cells to enter into premature S-phase by disrupting Rb-E2F 
complexes. The aim of the research work was to target the site of 
interaction of Rb1-E7 and p53-E6. A total of 88 compounds were 
selected for molecular screening, based on comprehensive literature 
survey for natural compounds with anticancer activity. Molecular 
docking analysis was carried out with Molegro Virtual Docker to study 
on their binding affinity toward the site of interaction of the viral 
oncoproteins and human tumor suppressor proteins. The docking 
analysis revealed that Nicandrenone a member of Withanolides family 
of chemical compounds as the most likely molecule that can be used as 
a candidate drug against HPV induced cervical cancer [29].
In this study, cellular tumor antigen p53, caspase 3, and mucosal addressin 
cell molecule 1 were successfully docked with apigenin using the BSP-
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Slim server. Based on the negative and lowest energy value (DGbind), the 
best docking orientation was chosen [30,31]. Docking analysis showed 
that there was a strong interaction between cellular tumor antigen p53 
and apigenin. It was the most favorable because it had the lowest energy 
value (−4.611 kcal/mol) when compared to caspase 3 and mucosal 
addressin cell adhesion molecule 1 which had −5.750 and −5.307 kcal/
mol, respectively (Table 7). The binding energy was calculated as the sum 
of the intermolecular energy and torsion energy.
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CONCLUSION
Cellular tumor antigen p53, caspase 3, and mucosal addressin cell 
adhesion molecule 1 were successfully docked with apigenin. The 
three protein models had a strong interaction between apigenin due 
to their negative binding energy. Thus, advance biochemical and in vivo 
investigations in silico interpretations of this protein-ligand model will 
support in designing more a potent structure-based drug.
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